Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis

被引：0

作者：

Jianyang Liu

Helena Idborg

Marina Korotkova

Kristina Lend

Ronald van Vollenhoven

Jon Lampa

Anna Rudin

Dan Nordström

Bjorn Gudbjornsson

Gerdur Gröndal

Till Uhlig

Kim Hørslev-Petersen

Merete Lund Hetland

Mikkel Østergaard

Michael Nurmohamed

Per-Johan Jakobsson

机构：

[1] Karolinska Institutet and Karolinska University Hospital,Division of Rheumatology, Department of Medicine

[2] Amsterdam University Medical Centers,Department of Rheumatology and Amsterdam Rheumatology Center

[3] University of Gothenburg Sahlgrenska Academy,Department of Rheumatology and Inflammation Research

[4] Helsinki University Hospital and University of Helsinki,Department of Medicine and Rheumatology

[5] Landspitali University Hospital,Department of Rheumatology

[6] University of Iceland,Faculty of Medicine

[7] Diakonhjemmet Hospital,Division of Rheumatology and Research

[8] University of Oslo,Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics

[9] Danish Hospital for the Rheumatic Diseases,Department of Clinical Medicine, Faculty of Health and Medical Sciences

[10] University of Southern Denmark,undefined

[11] Rigshospitalet,undefined

[12] University of Copenhagen,undefined

[13] Amsterdam Rheumatology and Immunology Center,undefined

来源：

Arthritis Research & Therapy | / 26卷

关键词：

Rheumatoid arthritis; tPGEM; tPGDM; 2,3-dinor-TXB; 2,3-dinor-6-keto-PGF; LTE; 12-HETE;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 44 条

[1]

Finckh A(2022)Global epidemiology of rheumatoid arthritis Nat Rev Rheumatol 18 591-602

[2]

Fleischmann RM(2023)Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2) Ann Rheum Dis 82 1516-26

[3]

Emery P(2020)Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial Ann Rheum Dis 79 464-71

[4]

Alivernini S(2022)The pathogenesis of rheumatoid arthritis Immunity 55 2255-70

[5]

Firestein GS(2008)The roles of prostanoids, leukotrienes, and platelet-activating factor in bone metabolism and disease Prog Lipid Res 47 107-26

[6]

McInnes IB(2014)Persisting eicosanoid pathways in rheumatic diseases Nat Rev Rheumatol 10 229-41

[7]

Hikiji H(2019)Quantitative metabolic profiling of urinary eicosanoids for clinical phenotyping J Lipid Res 60 1164-73

[8]

Korotkova M(2016)Prostaglandin D2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis Immun Inflamm Dis 4 64-9

[9]

Jakobsson P-J(2001)Difference in urinary 11-dehydro TXB2 and LTE4 excretion in patients with rheumatoid arthritis Prostaglandins Leukot Essent Fat Acids 65 301-6

[10]

Gómez C(2020)Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis Nat Commun 11 5420-13

← 1 2 3 4 5 →